Inhaled iloprost for the control of pulmonary hypertension

Sabine Krug, Armin Sablotzki, Stefan Hammerschmidt, Hubert Wirtz, Hans-Juergen Seyfarth, Sabine Krug, Armin Sablotzki, Stefan Hammerschmidt, Hubert Wirtz, Hans-Juergen Seyfarth

Abstract

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by an elevated pulmonary arterial pressure and vascular resistance with a poor prognosis. Various pulmonary and extrapulmonary causes are now recognized to exist separately from the idiopathic form of pulmonary hypertension. An imbalance in the presence of vasoconstrictors and vasodilators plays an important role in the pathophysiology of the disease, one example being the lack of prostacyclin. Prostacyclin and its analogues are potent vasodilators with antithrombotic, antiproliferative and anti-inflammatory qualities, all of which are important factors in the pathogenesis of precapillary pulmonary hypertension. Iloprost is a stable prostacyclin analogue available for intravenous and aerosolized application. Due to the severe side effects of intravenous administration, the use of inhaled iloprost has become a mainstay in PAH therapy. However, owing to the necessity for 6 to 9 inhalations a day, oral treatment is often preferred as a first-line therapy. Numerous studies proving the efficacy and safety of inhaled iloprost have been performed. It is therefore available for a first-line therapy for PAH. The combination with endothelin-receptor antagonists or sildenafil has shown encouraging effects. Further studies with larger patient populations will have to demonstrate the use of combination therapy for long-term treatment of pulmonary hypertension.

References

    1. Olschewski H. Dana Point: what is new in the diagnosis of pulmonary hypertension? Dtsch Med Wochenschr. 2008;133(S6):180–182.
    1. Olschewski H, Rose F, Gruenig E. Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med. 2001;138(6):367–377.
    1. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:7S–10S.
    1. D′Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Int Med. 1991;115(5):343–349.
    1. Gomberg-Maitland M, Preston IR. Prostacyclin therapy for pulmonary arterial hypertension: new directions. Semin Respir Crit Care Med. 2005;26(4):394–401.
    1. Welsh C, Hassell K, Badesch D, et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest. 1996;110:710–717.
    1. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70–75.
    1. Geraci MW, Gao B, Shepherd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 1999;103(11):1509–1515.
    1. Nagaya N, Yokoyama C, Kyotani S, et al. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation. 2000;102(16):2005–2010.
    1. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Resp Crit Care Med. 1999;159(6):1925–1932.
    1. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99:249–254.
    1. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539.
    1. Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest. 2002;121(5):1566–1571.
    1. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338(5):273–277.
    1. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–788.
    1. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425–434.
    1. Higenbottam TW, Butt AY, Dinh-Xaun AT, et al. Treatment of pulmonary hypertension with the continous infusion of a prostacyclin analogue, iloprost. Heart. 1998;79:175–179.
    1. Simmoneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Resp Crit Care Med. 2002;165(6):800–804.
    1. Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39(9):1496–1502.
    1. Barst RJ, McGoon M, McLaughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119–2125.
    1. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34(4):1188–1192.
    1. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension. Ann Intern Med. 1996;124(9):820–824.
    1. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol. 1986;30(1):61–68.
    1. Gessler T, Schmehl T, Hoeper MM, et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Resp J. 2001;17(1):14–19.
    1. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;343(19):1866–1870.
    1. South San Francisco, Calif: Actelion Pharmaceuticals US, Inc; 2006. Ventavis (iloprost) [package insert]
    1. Schermuly RT, Schulz A, Ghofrani A, et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J Pharmacol Exp Ther. 2002;303(2):741–745.
    1. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–329.
    1. Ewert R, Opitz C, Wensel R, et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z Kardiol. 2000;89(11):987–999.
    1. Walmrath D, Schneider T, Pilch J, et al. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet. 1993;342:961–962.
    1. Welte M, Zwissler B, Habazettl H, et al. PG12 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur Surg Res. 1993;25:329–340.
    1. Olschewski H, Ghofrani A, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Resp Crit Care Med. 1999;160(2):600–607.
    1. Wensel R, Opitz CF, Ewert R, et al. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation. 2000;101:2388–2392.
    1. Hoeper MM, Olschewski H, Ghofrani A, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol. 2000;35(1):176–182.
    1. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med. 2000;132(6):500–502.
    1. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342(25):1866–1870.
    1. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–329.
    1. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26(18):1895–1902.
    1. Fruhwald FM, Kjellström B, Perthold W, et al. Continous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost. Chest. 2003;124:351–359.
    1. Mereles D, Ewert R, Lodziewski S, et al. Effect of inhaled iloprost during off-medication time in patients with pulmonary arterial hypertension. Respiration. 2007;74:498–502.
    1. Domenighetti GM. Idiopathic pulmonary arterial hypertension and inhaled iloprost: Good night rebound effects? Respiration. 2007;74(5):496–497.
    1. Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J. 2003;24:356–365.
    1. Schenk P, Petkov V, Madl C, et al. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension. Chest. 2001;119:296–300.
    1. Hoeper MM, Spiekerkoetter E, Westerkamp V, et al. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J. 2002;20(2):339–343.
    1. Launay D, Hachulla E, Hatron PY, et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol. 2001;28(10):2252–2256.
    1. Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol. 2003;92(8):1007–1009.
    1. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257–2264.
    1. Lang IM. Chronic thromboembolic pulmonary hypertension – not so rare after all. N Engl J Med. 2004;350:2236–2238.
    1. Kramm T, Eberle B, Guth S, et al. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg. 2005;28(6):882–888.
    1. Webb SA, Stott S, van Heerden PV. The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism. Intensive Care Med. 1996;22(4):353–355.
    1. Roig Figueroa V, Herrero Pérez A, de la Torre Ferrera N, et al. Iloprost for Chronic thromboembolic pulmonary hypertension. Arch Bronconeumol. 2004;40(7):326–328.
    1. Ulrich S, Fischler M, Speich R, et al. Chronic Thromboembolic and Pulmonary Arterial Hypertension share acute vasoreactivity properties. Chest. 2006;130:841–846.
    1. Krug S, Hammerschmidt S, Pankau H, et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration. 2008;76(2):154–159.
    1. Ahmadi-Simab K, Koehler A, Gross WL. Sustained success of therapy with inhaled iloprost for severe pulmonary arterial hypertension associated with systemic sclerosis and pulmonary fibrosis. Clin Exp Rheumatol. 2007;25(5):760–762.
    1. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007;30(6):1038–1040.
    1. Schermuly RT, Krupnik E, Tenor H, et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care. 2001;164(9):1694–1700.
    1. Wilkens H, Guth A, Koenig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104(11):1218–1222.
    1. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42(1):158–164.
    1. Hoeper MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J. 2003;22(2):330–334.
    1. Seyfarth HJ, Pankau H, Hammerschmidt S, et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest. 2005;128(2):709–713.
    1. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257–1263.
    1. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28:691–694.
    1. Ramakrishna G, Sprung J, Ravi BS, et al. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol. 2005;45:1691–1699.
    1. Rinne T, Zwissler B. Intraoperative anaesthesiologic management of patients with pulmonary hypertension. Intensiv Notfallbeh. 2004;29(1):4–13.
    1. Roberts NV, Keast PJ. Pulmonary hypertension and pregnancy: a lethal combination. Anesth Intensive Care. 1990;18:366–374.
    1. Fischer LG, Van Aken H, Burkle H. Management of pulmonary hypertension: physiological and pharmacological considerations for anaesthesiologists. Anesth Analg. 2003;96:1603–1616.
    1. Fox C, Kalarickal PL, Yarborough MJ, et al. Perioperative management including new pharmacological vistas for patients with pulmonary hypertension for noncardiac surgery. Curr Opin Anaesthesiol. 2008;21:467–472.
    1. Khan MJ, Bhatt SB, Krye JJ. Anesthetic considerations for parturients with primary pulmonary hypertension: review of the literature and clinical presentation. Int J Obstet Anesth. 1996;5:36–42.
    1. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension. Pathophysiology and anesthetic approach. Anesthesiology. 2003;99(6):1415–1432.
    1. Subramaniam K, Yared JP. Management of pulmonary hypertension in the operating room. Sem Cardiothoracic Vasc Anesth. 2007;11(4):119–136.
    1. Sablotzki A, Starzmann W, Scheubel R, et al. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth. 2005;52(10):1076–1082.
    1. Haraldsson A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg. 2001;93(6):1439–1445.
    1. Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass ion cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth. 2008;22(3):406–413.
    1. Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest. 2007;131(4):977–983.
    1. Atz AM, Lefler AK, Fairbrother DL, et al. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertension crises. J Thorac Cardiovasc Surg. 2002;124:628–629.
    1. Hoeper MM, Olschewski H, Hossein A, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol. 2000;35:176–182.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi